5 Worst Performing Healthcare Stocks in 2023

Page 1 of 5

In this article, we discuss 5 worst performing healthcare stocks in 2023. If you want to read our detailed discussion about the biotech industry, head over to 15 Worst Performing Healthcare Stocks in 2023.

5. Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE)

YTD Share Price Decline as of August 13: 28.79% 

Number of Hedge Fund Holders: 17

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) is a biotechnology firm that is currently at the clinical-stage. It develops therapies for neurological disorders and is working on clinical trials for different medications. On August 2, Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) announced a Q2 GAAP loss per share of $0.63, beating Wall Street estimates by $0.06. The stock has plummeted nearly 29% year-to-date as of August 13, making Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) one of the worst performing healthcare companies this year. 

According to Insider Monkey’s first quarter database, 17 hedge funds were bullish on Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE), as compared to 16 in the last quarter. Joseph Edelman’s Perceptive Advisors held the largest share in the company, with 6.5 million shares worth $158.8 million.

Follow Cerevel Therapeutics Holdings Inc. (NASDAQ:CERE)

Page 1 of 5